Notice · content is for research purposes. The peptides described are not approved for human consumption and do not constitute medical advice.
In short: The evolution of incretin peptides in laboratory settings has progressed from GLP-1 mono-agonists (semaglutide) to dual GIP/GLP-1 agonists (tirzepatide) and innovative triple GLP-1/GIP/glucagon receptor agonists (retatrutide). This transition demonstrates a dose-dependent increase in body mass reduction and energy metabolism modulation in in vivo models.
Incretin mimetics are peptide hormones that regulate glucose metabolism and energy balance by activating specific G-protein coupled receptors (GPCRs). Initial research in this field focused exclusively on GLP-1 (glucagon-like peptide-1). The work of researchers such as Lotte Bjerre Knudsen at Novo Nordisk led to the development of Semaglutide — a molecule optimized for extended half-life and high receptor selectivity [1].
As peptide engineering advanced, researchers' focus shifted to polypharmacology — the integration of multiple receptor activities into a single molecule. This approach, pioneered by Richard DiMarchi at Indiana University, aimed to overcome the therapeutic plateaus observed with monotherapies. The result is the creation of dual and triple co-agonists that synergistically modulate various metabolic pathways.
Tirzepatide is the first successful dual agonist, combining GLP-1 with GIP (glucose-dependent insulinotropic polypeptide), demonstrating superior efficacy compared to selective Weight Loss GLP-1 agonists [2]. The newest frontier in this research direction is Retatrutide — a triple agonist that adds the glucagon receptor (GCG) to the binding profile, opening new avenues for researching energy expenditure and hepatic lipid clearance [3].
The mechanism of action of these peptides depends entirely on their affinity for their respective receptors. Semaglutide functions as a selective GLP-1 receptor agonist. By binding to GLP-1 receptors in the pancreas, it stimulates glucose-dependent insulin secretion. In the central nervous system (CNS), specifically in the hypothalamus and hindbrain, semaglutide modulates neurons responsible for satiety, leading to reduced food intake.
Tirzepatide introduces the concept of imbalanced dual agonism. Structurally based on the native GIP sequence, it exhibits high affinity for the GIP receptor (comparable to the native hormone) and approximately five times lower affinity for the GLP-1 receptor compared to native GLP-1. The addition of GIP signaling improves insulin sensitivity in adipose tissue and modulates lipid metabolism in a way that GLP-1 alone cannot achieve.
"The synergistic effect of GIP and GLP-1 receptor agonism in tirzepatide rewrites our understanding of incretin biology, proving that GIP, once considered obesogenic, is actually a potent metabolic optimizer in the presence of GLP-1 signaling."
Retatrutide builds upon this model by incorporating glucagon agonism. While GLP-1 and GIP primarily suppress appetite and regulate insulin, the glucagon receptor (GCGR) directly increases energy expenditure (thermogenesis) and stimulates lipolysis in the liver. GCGR activation traditionally raises blood sugar, but within the retatrutide structure, the simultaneous activation of GLP-1 and GIP neutralizes this diabetogenic effect, leaving only the benefits for lipid clearance and basal metabolic rate modulation.
To be effective in once-weekly in vivo models, native peptide sequences must be protected from rapid degradation by the DPP-4 (dipeptidyl peptidase-4) enzyme and possess reduced renal clearance. These pharmacokinetic challenges are addressed through specific amino acid substitutions and the acylation of the molecules with fatty acids.
In semaglutide, protection against DPP-4 is achieved by substituting alanine with alpha-aminoisobutyric acid (Aib) at position 8. To extend the half-life, a C-18 fatty diacid (stearic diacid) is attached to lysine at position 26 via a hydrophilic gamma-glutamate spacer. This modification allows for strong but reversible binding to plasma albumin, providing a half-life of approximately 165 hours in humans [1].
Tirzepatide employs a different acylation strategy. It contains a C-20 fatty diacid (eicosanedioic acid) attached to lysine at position 20 via a hydrophilic linker. This longer chain provides a half-life of about 116 hours. Interestingly, tirzepatide's structure allows for a specific conformation that grants it the ability to fully activate the GIP receptor while activating the GLP-1 receptor in a manner that minimizes receptor internalization (biased agonism).
Retatrutide also relies on a C-20 fatty diacid to extend its half-life. However, its peptide backbone is heavily modified to accommodate the three receptor affinities. It includes multiple Aib substitutions to protect against proteolytic degradation and specific amino acid residues that balance binding to GLP-1, GIP, and GCG receptors without causing steric hindrance.
The following table summarizes the key structural and pharmacological differences between the three generations of incretin mimetics, providing a clear baseline for selection when planning in vitro and in vivo studies.
| Characteristic | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Primary targets | GLP-1 | GLP-1, GIP | GLP-1, GIP, GCGR |
| Number of amino acids | 31 | 39 | 39 |
| Modification (Fatty acid) | C-18 diacid | C-20 diacid | C-20 diacid |
| Half-life (in vivo models) | ~165 hours | ~116 hours | ~144 hours |
| Acylation position | Lys26 | Lys20 | Lys17 |
| Glucagon activity | Zero | Zero | High |
This evolution in peptide design reflects the shift from simple receptor activation to complex, multi-component metabolic modulation.
The efficacy of these peptides regarding weight loss has been the subject of massive clinical trials, which provide quantitative data on their effectiveness. It is important to analyze the results from key phase 3 trials (or phase 2 for retatrutide) to understand the dose-dependent response.
In the STEP-1 trial (published in the New England Journal of Medicine, 2021), researchers analyzed the effect of semaglutide at a dose of 2.4 mg weekly. The results showed an average body mass reduction of 14.9% at week 68 in subjects with overweight or obesity, compared to 2.4% in the placebo group [1]. These data established semaglutide as the gold standard for mono-agonists.
Tirzepatide demonstrated significantly higher efficacy in the SURMOUNT-1 trial (NEJM, 2022). At the maximum studied dose of 15 mg weekly, tirzepatide achieved an average body mass reduction of 22.5% at week 72 [2]. This leap in efficacy is attributed to the inclusion of GIP receptor agonism, which not only suppresses appetite but also improves lipid metabolism and reduces fat depots more effectively than pure GLP-1 agonism.
Phase 2 data for retatrutide (TRIUMPH-1 trial, NEJM, 2023) showed an unprecedented average body mass reduction of 24.2% in just 48 weeks at a dose of 12 mg [3].
Furthermore, retatrutide showed a complete normalization of liver fat in over 85% of subjects with non-alcoholic fatty liver disease (NAFLD) — an effect directly attributed to the glucagon component of the molecule, which stimulates hepatic beta-oxidation.
The choice between semaglutide, tirzepatide, and retatrutide for laboratory research depends entirely on the specific goals of the experimental model.
Researchers should choose semaglutide when the focus is on isolated GLP-1 receptor signaling. As the most widely researched molecule in its class, it serves as an excellent control peptide in comparative studies. Semaglutide is also preferred in studies of cardiovascular endpoints in animal models, as its safety and efficacy profile in this area is the most well-documented.
Tirzepatide is the optimal choice for studies targeting the synergy between GIP and GLP-1. It is particularly valuable in in vitro adipocyte models, where researchers study insulin sensitivity and lipid accumulation. Tirzepatide has been shown to modulate the expression of genes related to lipogenesis in a manner distinct from selective GLP-1 agonists.
Retatrutide is best suited for advanced metabolic research, especially those focused on hepatic steatosis (NASH/MASH) and the modulation of energy expenditure. Its triple agonism allows researchers to observe the effects of increased thermogenesis (via the glucagon receptor) combined with suppressed caloric intake (via GLP-1/GIP), making it ideal for models of severe diet-induced obesity (DIO mice).
The main difference lies in receptor specificity. Semaglutide is a selective mono-agonist, binding only to the GLP-1 receptor. Tirzepatide is a dual agonist that binds to both GLP-1 and GIP receptors, leading to synergistic effects on insulin sensitivity and lipid metabolism in in vitro and in vivo models.
Glucagon agonism is included to stimulate energy expenditure (thermogenesis) and accelerate lipolysis in the liver. While GLP-1 and GIP reduce energy intake, glucagon increases energy expenditure, leading to more pronounced body mass reduction and rapid clearance of liver fat in clinical trials.
The half-life of semaglutide is about 165 hours, tirzepatide is ~116 hours, and retatrutide is ~144 hours. This is achieved through acylation — attaching long-chain fatty acids (C-18 or C-20 diacids) that bind reversibly to albumin in the blood, protecting the peptides from rapid renal clearance and enzymatic degradation.
Yes, all of them are being studied for liver effects, but retatrutide shows the most promising results. In phase 2 clinical trials, the triple agonist demonstrated the ability to normalize liver fat levels in a significantly higher percentage of subjects compared to mono- and dual agonists.
In lyophilized (powder) form, these peptides should be stored at temperatures below -20°C for long-term stability. After reconstitution with bacteriostatic water for in vitro experiments, the solutions are typically stored at 2-8°C and must be used within their specific stability period to avoid aggregation or degradation.
The evolution from semaglutide through tirzepatide to retatrutide illustrates the progression of peptide science from mono-target interventions to complex polypharmacology. Clinical data clearly show that integrating additional receptor targets (GIP and glucagon) into the base GLP-1 architecture leads to dose-dependent and synergistic improvements in metabolic parameters. For researchers, these molecules provide unprecedented tools for deconstructing the pathophysiology of obesity and metabolic disorders at the molecular level.
[1] Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. PMID: 33567185
[2] Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 387(3), 205–216. PMID: 35658024
[3] Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England Journal of Medicine, 389(6), 514–526. PMID: 37366315
[4] Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology, 10, 155. PMID: 30971486
No comments yet. Be the first.
Comments are reviewed before publishing.
